How much does Cytocell Limited make?

Cytocell Limited reported revenue of £15.5m and £3.4m profit in the year to 31 Mar 2025, according to its accounts filed at Companies House.

How many employees does Cytocell Limited have?

Cytocell Limited reported an average of 76 employees in the year to 31 Mar 2025.

Is Cytocell Limited profitable?

Yes — Cytocell Limited reported a profit of £3.4m in the year to 31 Mar 2025.

Company No. 04231155 · Incorporated 8 Jun 2001

Cytocell Limited

Registered name: CYTOCELL LIMITED

Part of Sysmex Corporation group

Cytocell Limited made £15.5m revenue and £3.4m profit in the year to 31 Mar 2025.

Cytocell Limited’s revenue grew 16% to £15.5m in the year to 31 Mar 2025, with £3.4m profit and 76 employees. The company is classified under “other human health activities” and is based in Cambridge; we hold 4 years of its filed accounts.

Full P&L filedSection Q · Human health and social workSIC 86900Other human health activities

Status: Active
Location: Cambridge, East of England
Age: 25 yrs · since 2001
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The Company's immediate controlling party is Oxford Gene Technology IP Limited, incorporated in England & Wales. In the opinion of the directors, the Company's ultimate parent Company and ultimate con”

Latest accounts · year to 31 Mar 2025

Key figures

Operating leverageDoing more with less

Revenue

£15.5m

Growth ▲16.4%

Profit

£3.4m

Growth ▲23.5%

Profit margin

22.1%

Gross 65%

Employees

Change ▼1.3%

Profit / employee

£45.1k

Revenue/employee £204k

Profitable streak

4yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Mar 2022	31 Mar 2023	31 Mar 2024	31 Mar 2025
Disclosure	Full P&L	Full P&L	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£11.7m	£13.4m	£13.3m	£15.5m
Cost of sales	£4m	£4.3m	£4.8m	£5.4m
Gross profit	£7.7m	£9.1m	£8.5m	£10.1m
Operating profit	£3.9m	£4.5m	£2.9m	£3.8m
Profit before tax	£3.6m	£4.1m	£2.6m	£3.6m
Profit after tax	£3.2m	£3.5m	£2.8m	£3.4m
Profit (best available)	£3.2m	£3.5m	£2.8m	£3.4m
Staff costs	£2.9m	£3.6m	£4.1m	£4.5m
Employees (average)	65	72	77	76
Ratios
Profit margin	27%	26.2%	20.9%	22.1%
Gross margin	65.8%	67.9%	64.1%	65%
Revenue per employee	£180k	£186k	£173k	£204k
Profit per employee	£48.6k	£48.7k	£36.1k	£45.1k
Growth (year on year)
Revenue growth	—	▲14.2%	▼0.6%	▲16.4%
Profit growth	—	▲11%	▼20.9%	▲23.5%
Headcount growth	—	▲10.8%	▲6.9%	▼1.3%
Balance sheet — indirect signals, not revenue
Cash at bank	£1.2m	£1.5m	£896k	£664k
Net assets	£28.7m	£32.2m	£34.9m	£38.4m
Fixed assets	£7.3m	£6.6m	£5.9m	£5.3m
Current assets	£44m	£50.7m	£57.4m	£66.3m
Debtors	£884k	£734k	£1.7m	£1m
Deferred income	£441k	£495k	£701k	£647k
Source	Accounts · bulk data Dec 2023	Accounts · bulk data Dec 2023	FullAccounts · bulk data Dec 2024	FullAccounts · bulk data Dec 2025

Derived from the latest filing

How the business works

Profit margin: 22.1%; Profit ÷ revenue.
Gross margin: 65%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £204k; Revenue ÷ average employees.
Profit per employee: £45.1k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 34.2%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 4.2%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 6.8%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲10%; Now £38.4m
Cash at bank: ▼26%; Now £664k
Headcount: ▼1%; Now 76
Deferred income: ▼8%; Now £647k
Fixed assets: ▼10%; Now £5.3m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Sysmex Corporation (registered outside the UK register)ultimate parent75–100%
Oxford Gene Technology IP Limited75–100%
Cytocell Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (3)

Oxford Gene Technology (Operations) LtdRev. £10.3m · Profit −£353k
Oxford Gene Technology (Southern) LimitedRev. — · Profit −£581
Oxford Gene Technology LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Mar 2025 (profit £3.4m), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.